Genmab — December 2024
-
https://www.biospace.com/drug-development/gsk-touts-42-survival-benefit-for-blenrep-in-multiple-myeloma-strengthening-bid-for-market-return?_gl=1*10oq5ns*_up*MQ.._gaMzc1NzEzMDI4LjE3MzM4NDI3NDA._ga_Q90M6MWJZ4MTczMzg0MjczOC4xLjAuMTczMzg0MjczOC4wLjAuMA..
-
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.
BioSpace (www.biospace.com)
-
Evaluate Pharma forecast Darzalex 2025 $13.17bn https://x.com/NatRevDrugDisc/status/1866496363371941939
-
jeg bliver altid så glad når Nohope skriver herinde. Det minder mig om, at der er plads til alle bidrag.
-
there is just too much news on the JNJ antibodies to post all , but let's pick 1 - Vincent Rajkumar
@VincentRK
Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma https://x.com/VincentRK/status/1866205101595189678 -
-
Genmab/Jan bør lytte nøje her og sikre, at de bliver first movers inden for de molekyler og proteiner og deres felt, som Huang også omtaler. Selvom klippet handler om Tesla, er pointen, at Genmab kan accelerere deres pipeline ved at anvende den samme teknologi, før konkurrenterne får overtaget. https://www.youtube.com/watch?v=5OOuSzcQNGg Huang snakker om et start op firma i starten ca. 30 sek inde
-
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial - - These data confirm luvelta’s robust response rate in patients with late-stage ovarian cancer expressing a broad range of folate receptor alpha (FRα) - - Neutropenia well-managed; no new safety findings - - Luvelta is positioned for an Accelerated Approval application in mid-2027 - SOUTH SAN FRANCISCO, Calif., D
Yahoo Finance (finance.yahoo.com)
-
Lidt fra konkurrenten Roche https://x.com/bertrandbio/status/1866543177144127791?s=61&t=JauvgjicW74kU8sNN3xEFA
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind